Dr. West Discusses Results of the Phase III FLAURA Study in NSCLC
September 20th 2017H. Jack West, MD, medical oncologist, Swedish Cancer Institute of Swedish Medical Center, discusses the results of the phase III FLAURA study of frontline osimertinib (Tagrisso) in patients with EGFR-mutant non–small cell lung cancer (NSCLC).
Watch
The Optimal Duration of Pertuzumab Treatment for Patients With HER2+ Breast Cancer
September 19th 2017Gunter von Minckwitz, MD, PhD, president of the German Breast Group in Neu-Isenburg, Germany, discusses questions still surrounding the optimal duration of pertuzumab (Perjeta) treatment for patients with HER2-positive breast cancer.
Watch
How the Results of COMBI-AD and CheckMate-238 Will Impact Melanoma Care
September 18th 2017Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses how the results of the COMBI-AD study and the CheckMate-238 study will impact the care of patients with melanoma.
Watch
Impact of CheckMate-238 Results for Patients With Melanoma
September 18th 2017Jeffrey S. Weber, MD, PhD, deputy director of the Laura and Isaac Perlmutter Cancer Center, co-director of the Melanoma Program, and head of Experimental Therapeutics at NYU Langone Medical Center, discusses how results of the CheckMate-238 study will impact patients with melanoma.
Watch
Exploring Cabozantinib With Nivolumab and Ipilimumab in Urothelial Carcinoma
September 18th 2017Andrea B. Apolo, MD, principal investigator and the head of the Bladder Cancer Section in the Genitourinary Malignancies Branch at the National Cancer Institute’s Center for Cancer Research, discusses a phase I study of cabozantinib (Cabometyx) plus nivolumab (Opdivo) and cabozantinib plus nivolumab with ipilimumab (Yervoy) in patients with refractory metastatic urothelial carcinoma and other genitourinary tumors.
Watch
Remaining Questions With Multiple Myeloma Treatment
September 15th 2017Robert Orlowski, MD, PhD, Florence Maude Thomas Cancer Research professor and chair, ad interim, Department of Lymphoma & Myeloma at The University of Texas MD Anderson Cancer Center, discusses remaining questions with multiple myeloma treatment.
Watch
Combining an Anti-LAG-3 Antibody With Nivolumab in Melanoma
September 13th 2017Paolo A. Ascierto, MD, director at the Unit of Melanoma, Cancer Immunotherapy and Innovative Therapy, National Tumor Institute Fondazione G. Pascale, discusses the initial efficacy findings for the anti-LAG-3 antibody BMS-986016 plus nivolumab in patients with immunotherapy-relapsed/refractory melanoma.
Watch
Dr. Langer Discusses Current Treatment Strategies for Patients With Non-Driver Nonsquamous NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine, Hospital of the University of Pennsylvania, discusses current treatment strategies for patients with non-driver nonsquamous non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Ongoing Clinical Trials for Patients With Non-Driver NSCLC
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses ongoing clinical trials for patients with non-driver non-small cell lung cancer (NSCLC).
Watch
Dr. Langer Discusses Remaining Challenges With the Non-Driver NSCLC Population
September 13th 2017Corey J. Langer, MD, Perelman Center for Advanced Medicine; Hospital of the University of Pennsylvania, discusses remaining challenges in the treatment of patients with non-driver non-small cell lung cancer.
Watch
Dr. Jagannath Discusses the STORM and STOMP Trials for Patients With Multiple Myeloma
September 12th 2017Sundar Jagannath, MDDS, professor, Medicine, Hematology, and Medical Oncology, Mount Sinai Hospital, discusses the STORM and STOMP clinical trials in patients with multiple myeloma.
Watch